Synthetic Human TLR9-LRR11 Peptide Attenuates TLR9 Signaling by Binding to and thus Decreasing Internalization of CpG...

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Toll-like receptor 9 (TLR9) recognizes bacterial DNA/CpG oligodeoxynucleotides (CpG ODN).
• Overactivation of TLR9 signaling contributes to immune system dysregulation.
• Targeting TLR9 is a potential therapeutic strategy for inflammatory conditions.

Purpose of the Study:

• To investigate a synthetic peptide (SP) as a potential inhibitor of TLR9 activity.
• To elucidate the mechanism by which SP modulates CpG ODN/TLR9 interactions.
• To evaluate SP's efficacy in attenuating TLR9-mediated immune responses.

Main Methods:

• Utilized RAW264.7 cells to assess the effect of SP on CpG ODN stimulation.
• Measured cytokine release (TNF-α, IL-6) and key signaling pathway activation (IκBα, ERK, NF-κB/p65).
• Quantified CpG ODN internalization using fluorescently labeled ODN and determined binding affinity (KD).

Main Results:

• SP specifically inhibited CpG ODN-induced TNF-α and IL-6 release, but not LPS or PAM3CSK4.
• SP dose-dependently reduced TLR9-driven phosphorylation of IκBα and ERK, and NF-κB/p65 activation.
• SP decreased CpG ODN internalization, with inhibition reversed by unlabeled CpG ODN, indicating direct binding.

Conclusions:

• The synthetic peptide SP acts as a specific antagonist of CpG ODN/TLR9 signaling.
• SP functions by binding to CpG ODN, reducing its cellular uptake and subsequent pathway activation.
• SP demonstrates potential as a therapeutic agent to block TLR9-mediated immune responses.